Lexicon up 4% on positive early-stage data on neuropathic pain candidate LX9211

Dec. 05, 2019 11:56 AM ETLexicon Pharmaceuticals, Inc. (LXRX)LXRXBy: Douglas W. House, SA News Editor
  • Lexicon Pharmaceuticals (LXRX +4%) is up on below-average volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers.
  • LX9211 demonstrated a favorable safety profile and pharmacokinetic activity supportive of once-daily dosing. The most common adverse events were headache and dizziness.
  • Small molecule LX9211 inhibits an enzyme called adaptor-associated protein kinase 1 (AAK1). The company acquired exclusive rights from development partner Bristol-Myers Squibb two years ago.
  • Development is ongoing.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.